丙型肝炎的分子即时检测:现有技术、研发管线与有前景的未来方向
本文综述丙型肝炎病毒(HCV)分子即时检测技术的现状,讨论现有设备(近即时与真正即时)的优势与局限,并分析分子检测改变诊断医学的潜力及在常规临床中更广泛应用的挑战。
要点
- 丙型肝炎病毒(HCV)仍是重大公共卫生问题,尽管已有有效治疗。
- 在许多地区,即时诊断HCV感染是扩大诊疗可及性的关键。
- 需要准确、易用且负担得起的诊断工具以实现分散检测和一站式中心。
核心结论
- 需要准确、易用且负担得起的诊断工具以实现分散检测和建立一站式中心,从而弥合诊疗级联中的缺口,帮助发现中低收入国家及高收入国家高危人群中数百万未确诊的HCV感染者。
研究设计与样本
- 综述:检视即时分子检测技术的现状、现有设备(近即时与真正即时)的优势与局限、分子检测改变诊断医学的潜力及更广泛应用的挑战。
主要发现
- 在许多地区,即时诊断HCV感染是扩大诊疗可及性的关键。
- 需要准确、易用且负担得起的诊断工具以实现分散检测和建立一站式中心。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatitis C virus (HCV) remains a major public health problem, despite the availability of effective treatments. In many areas, the ability to diagnose HCV infection at the point of care is key to scaling up access to care and treatment. To achieve this, an accurate, easy-to-use, and affordable diagnostic tool is required-this would enable decentralized testing and the creation of one-stop centers to eliminate gaps in the care cascade, which would help reach the millions of people with undiagnosed HCV infection in low- and middle-income countries and high-risk populations in high-income countries. In this review, we examine the current state of point-of-care molecular technologies, the advantages and limitations of currently available devices (both near- and true-point-of-care), the potential of molecular testing to transform diagnostic medicine in the future, and the challenges that need to be addressed for broader adoption of this technology in routine clinical practice.
引用
- Ivanova Reipold E, Shilton S, Donolato M, et al. Molecular Point-of-Care Testing for Hepatitis C: Available Technologies, Pipeline, and Promising Future Directions. J Infect Dis. 2024. PMID: 37897429. doi:10.1093/infdis/jiad463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。